The Calcium Channel Inhibitor Nimodipine Shapes the Uveitogenic T Cells and Protects Mice from Experimental Autoimmune Uveitis through the p38–MAPK Signaling Pathway
- 15 December 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (12) , 2933-2943
Abstract
Autoimmune uveitis (AU) is a sight-threatening ocular inflammatory disorder, characterized by massive retinal vascular leakage and inflamed lesions with infiltration of the uveitogenic T cells in the retina and disorders of the T cell–related immune response in the system. Stimulation of TCRs can trigger calcium release and influx via Ca2+ channels and then transmit signals from the surface to the nucleus, which are important for energy metabolism, proliferation, activation, and differentiation. Inhibition of Ca2+ influx by pharmacological modulation of Ca2+ channels may suppress T cell function, representing a novel anti-inflammatory strategy in the treatment of AU. This study investigated the effects of the l-type voltage-gated calcium channel blocker nimodipine in experimental AU (EAU). Nimodipine was found to not only decrease the clinical and histopathological inflammation score of EAU (C57BL/6J mice) but also dwindle the infiltration of uveitogenic CD4+ T cells into the retina. Moreover, nimodipine decreased the effector T cells and increased the regulatory T cells in the immune system. In vitro, nimodipine reduced the effector T cell differentiation of the IRBP1–20–specific CD4+ T cells of EAU mice and LPS-stimulated PBMCs of uveitis patients. Meanwhile, nimodipine suppressed the energy metabolism, proliferation, activation, and Th1 cell differentiation of T cells. Further studies on RNA sequencing and molecular mechanisms have established that nimodipine alleviates EAU by regulating T cells response through the p38–MAPK pathway signaling. Taken together, our data reveal a novel therapeutic potential of the l-type Ca2+ channels antagonist nimodipine in AU by regulating the balance of T cell subsets. Key Points Nimodipine alleviates EAU by regulating T cells through the p38–MAPK pathway. Nimodipine suppresses the T cells on proliferation, activation, and differentiation.Keywords
Funding Information
- the National Science Foundation of China (8187040615)
- Guangdong Basic and Applied Basic Research Foundation (2019A1515110093)
This publication has 32 references indexed in Scilit:
- Nimodipine inhibits IL‐1β release stimulated by amyloid β from microgliaBritish Journal of Pharmacology, 2012
- Ion channels and transporters in lymphocyte function and immunityNature Reviews Immunology, 2012
- The CaV1.4 Calcium Channel Is a Critical Regulator of T Cell Receptor Signaling and Naive T Cell HomeostasisImmunity, 2011
- Verapamil protects dopaminergic neuron damage through a novel anti-inflammatory mechanism by inhibition of microglial activationNeuropharmacology, 2011
- Identification of ROS Using Oxidized DCFDA and Flow-Cytometry2009
- Calcium signaling in immune cellsNature Immunology, 2008
- TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1Nature Medicine, 2007
- Critical role for the β regulatory subunits of Cav channels in T lymphocyte functionProceedings of the National Academy of Sciences, 2006
- Incidence and prevalence of uveitis in Northern California The Northern California Epidemiology of Uveitis StudyOphthalmology, 2004
- Causes and frequency of blindness in patients with intraocular inflammatory disease.British Journal of Ophthalmology, 1996